High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. In this study, we analyzed the outcome of 84 patients at 3...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Marco, José A., Jiménez, Javier López, Recasens, Valle, Zarzoso, Miguel Fernández, González-Barca, Eva, De Marcos, Nieves Somolinos, Ramírez, M. Jose, Parraga, Francisco Javier Peñalver, Yañez, Lucrecia, De La Serna Torroba, Javier, Malo, Maria Dolores Garcia, Ariznavarreta, Guillermo Deben, Persona, Ernesto Perez, Guinaldo, M. Angeles Ruiz, De Paz Arias, Raquel, Llanos, Elena Bañas, Jarque, Isidro, Valle, M. del Carmen Fernandez, Tatay, Ana Carral, De Oteyza, Jaime Perez, Martin, Eva Maria Donato, Fernández, Inmaculada Perez, Martinez, Rafael Martinez, Costa, M. Angeles Andreu, Champ, Diana, Suarez, Julio García, Díaz, Marcos González, Ferrer, Secundino, Carbonell, Félix, García-Vela, José A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821631/
https://www.ncbi.nlm.nih.gov/pubmed/30890600
http://dx.doi.org/10.3324/haematol.2018.204891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821631/
https://www.ncbi.nlm.nih.gov/pubmed/30890600
http://dx.doi.org/10.3324/haematol.2018.204891

Ejemplares similares